Trials / Completed
CompletedNCT01174043
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-08-03
- Last updated
- 2023-10-13
- Results posted
- 2015-03-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01174043. Inclusion in this directory is not an endorsement.